Overview

A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The primary hypothesis of this study is that concomitant multiple-dose administration of PN 400 does not interfere with the platelet inhibitory effects of enteric-coated low-dose aspirin (81 mg), as measured by serum thromboxane B2 inhibition.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
POZEN
Treatments:
Aspirin